Claims
- 1. A pharmaceutical formulation comprising, in an amount effective to hydrate lung mucous secretions, and in a pharmaceutically acceptable carrier, a compound of Formula (I):
- 2. A pharmaceutical formulation according to claim 1, further comprising a compound selected from the group consisting of amiloride, benzamil and phenamil, or a pharmaceutically acceptable salt thereof.
- 3. A pharmaceutical formulation according to claim 1, wherein said carrier is a liquid carrier.
- 4. A pharmaceutical formulation according to claim 1, wherein said carrier is a solid particulate carrier.
- 5. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I below, or a pharmaceutically acceptable salt thereof, in an amount effective to hydrate lung mucous secretions:
- 6. A method according to claim 5, wherein said compound is delivered by administering an aerosol suspension of respirable particles comprised of said compound to the lungs of said subject.
- 7. A method according to claim 6, wherein said particles are selected from the group consisting of solid particles and liquid particles.
- 8. A method according to claim 5, further comprising concurrently administering a compound selected from the group consisting of amiloride, benzamil and phenamil to said subject in an amount effective to inhibit the reabsorption of water from lung mucous secretions.
- 9. A method of treating cystic fibrosis in a human subject in need of such treatment, comprising administering by inhalation an aerosol suspension of respirable particles to the respiratory system of said subject, said particles comprised of a compound of Formula I below, or a pharmaceutically acceptable salt thereof:
- 10. A method according to claim 9, wherein said compound is delivered by administering an aerosol suspension of respirable particles comprised of said compound to the lungs of said subject.
- 11. A method according to claim 9, wherein said particles are selected from the group consisting of solid particles and liquid particles.
- 12. A method according to claim 9, further comprising concurrently administering a compound selected from the group consisting of amiloride, benzamil and phenamil to said subject in an amount effective to inhibit the reabsorption of water from lung mucous secretions.
- 13. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I below, or a pharmaceutically acceptable salt thereof, in an amount effective to hydrate lung mucous secretions:
- 14. A method according to claim 13, wherein said compound is delivered by administering an aerosol suspension of respirable particles comprised of said compound to the lungs of said subject.
- 15. A method according to claim 13, wherein said particles are selected from the group consisting of solid particles and liquid particles.
- 16. A method according to claim 13, further comprising concurrently administering a compound selected from the group consisting of amiloride, benzamil and phenamil to said subject in an amount effective to inhibit the reabsorption of water from lung mucous secretions.
- 17. A method of treating cystic fibrosis in a human subject in need of such treatment, comprising administering by inhalation an aerosol suspension of respirable particles to the respiratory system of said subject, said particles comprised of a compound of Formula I below, or a pharmaceutically acceptable salt thereof:
- 18. A method according to claim 17, wherein said compound is delivered by administering an aerosol suspension of respirable particles comprised of said compound to the lungs of said subject.
- 19. A method according to claim 18, wherein said particles are selected from the group consisting of solid particles and liquid particles.
- 20. A method according to claim 17, further comprising concurrently administering a compound selected from the group consisting of amiloride, benzamil and phenamil to said subject in an amount effective to inhibit the reabsorption of water from lung mucous secretions.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of commonly owned, co-pending U.S. patent application Ser. No. 08/486,988, filed Jun. 7, 1995, the disclosure of which is incorporated by reference herein in its entirety.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09303491 |
Apr 1999 |
US |
Child |
09850609 |
May 2001 |
US |
Parent |
08853056 |
May 1997 |
US |
Child |
09303491 |
Apr 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08486988 |
Jun 1995 |
US |
Child |
08853056 |
May 1997 |
US |